Literature DB >> 21912082

Clinical features and outcome of acute exacerbation of interstitial pneumonia: collagen vascular diseases-related versus idiopathic.

Ryo Tachikawa1, Keisuke Tomii, Hiroyuki Ueda, Kazuma Nagata, Shigeki Nanjo, Ayako Sakurai, Kyoko Otsuka, Reiko Kaji, Michio Hayashi, Nobuyuki Katakami, Yukihiro Imai.   

Abstract

BACKGROUND: Relatively little is known about acute exacerbation (AE) of interstitial pneumonia associated with collagen vascular diseases (CVD-IPs).
OBJECTIVES: This study was aimed at clarifying clinical characteristics and outcome in AE of CVD-IPs, compared with those of idiopathic interstitial pneumonias (IIPs).
METHODS: We retrospectively reviewed 112 admission cases with suspected AE of CVD-IPs or IIPs during 2003-2009. IIPs were diagnosed with idiopathic pulmonary fibrosis (IPF) or non-IPF, mostly based on radiologic findings. Of these, 15 AEs of CVD-IPs (6 rheumatoid arthritis, 6 dermatomyositis and 3 systemic sclerosis) and 47 AEs of IIPs (13 IPF and 34 non-IPF) were included.
RESULTS: The clinical characteristics in AE of CVD-IPs were similar to those of IIPs, except for younger age (63.3 ± 6.8 vs. 73.8 ± 9.1 years; p = 0.0001) and higher PaO(2)/FiO(2) at the onset of AE (205 ± 81.2 vs. 145 ± 53.8 mm Hg; p = 0.002) in the former. Dermatomyositis-related interstitial pneumonia (IP) showed a relatively indolent onset and was often associated with worsening control of the underlying disease, whereas AE of other CVD-IPs resembled that of IIPs. 90-day mortality of 33% in AE of CVD-IPs was similar to that of IIPs (44%; p = 0.44) or non-IPF (34%; p = 0.94), but was significantly better than that of IPF (69%; p = 0.04).
CONCLUSION: Clinical features and outcome in AE of CVD-IPs were similar, if not identical, to those of IIPs, having a significant impact on the clinical course. AE of advanced IPF with typical radiologic features seems to have higher mortality compared with other forms of IP.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2011        PMID: 21912082     DOI: 10.1159/000329893

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  35 in total

1.  Pharmacological treatment of acute exacerbation of idiopathic pulmonary fibrosis: a retrospective study of 88 patients.

Authors:  Susumu Sakamoto; Hiroshige Shimizu; Takuma Isshiki; Atsuko Kurosaki; Sakae Homma
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2019-05-01       Impact factor: 0.670

Review 2.  Management of interstitial lung disease associated with connective tissue disease.

Authors:  Stephen C Mathai; Sonye K Danoff
Journal:  BMJ       Date:  2016-02-24

3.  Acute exacerbation of interstitial lung diseases secondary to systemic rheumatic diseases: a prospective study and review of the literature.

Authors:  Andreina Manfredi; Marco Sebastiani; Stefania Cerri; Caterina Vacchi; Roberto Tonelli; Giovanni Della Casa; Giulia Cassone; Amelia Spinella; Pancaldi Fabrizio; Fabrizio Luppi; Carlo Salvarani
Journal:  J Thorac Dis       Date:  2019-04       Impact factor: 2.895

4.  [Acute on chronic respiratory failure in interstitial pneumonias].

Authors:  M Westhoff
Journal:  Med Klin Intensivmed Notfmed       Date:  2014-08-16       Impact factor: 0.840

Review 5.  Acute Exacerbation of Idiopathic Pulmonary Fibrosis.

Authors:  Tomoo Kishaba
Journal:  Eurasian J Med       Date:  2017-10

6.  Outcomes and Mortality Prediction Model of Critically Ill Adults With Acute Respiratory Failure and Interstitial Lung Disease.

Authors:  Whitney D Gannon; David J Lederer; Mauer Biscotti; Azka Javaid; Nina M Patel; Daniel Brodie; Matthew Bacchetta; Matthew R Baldwin
Journal:  Chest       Date:  2018-01-17       Impact factor: 9.410

Review 7.  Interstitial lung disease in connective tissue disease--mechanisms and management.

Authors:  Athol U Wells; Christopher P Denton
Journal:  Nat Rev Rheumatol       Date:  2014-09-30       Impact factor: 20.543

8.  Clinical significance of Charlson comorbidity index as a prognostic parameter for patients with acute or subacute idiopathic interstitial pneumonias and acute exacerbation of collagen vascular diseases-related interstitial pneumonia.

Authors:  Kota Murohashi; Yu Hara; Yusuke Saigusa; Nobuaki Kobayashi; Takashi Sato; Masaki Yamamoto; Makoto Kudo; Takeshi Kaneko
Journal:  J Thorac Dis       Date:  2019-06       Impact factor: 2.895

9.  A systematic review of the incidence, risk factors and prognosis of acute exacerbation of systemic autoimmune disease-associated interstitial lung disease.

Authors:  Hiroyuki Kamiya; Ogee Mer Panlaqui
Journal:  BMC Pulm Med       Date:  2021-05-05       Impact factor: 3.317

10.  Feasibility and Outcomes of a Standardized Management Protocol for Acute Exacerbation of Interstitial Lung Disease.

Authors:  Colin J Adams; Karan Chohan; Dmitry Rozenberg; John Kavanagh; Gerhard Greyling; Shane Shapera; Jolene H Fisher
Journal:  Lung       Date:  2021-08-04       Impact factor: 2.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.